Fisetin in Mild Alzheimer's Disease

Fisetin Intervention Study in Mild Alzheimer's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07279714

Acronym

FIS-AD

Enrollment

Registered

2025-12-12

Start date

2026-01-27

Completion date

2026-07-21

Last updated

2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease, Alzheimer s Disease, Mild Cognitive Disorder, Neurocognitive Disorder, Neurocognitive Disorders, Mild

Keywords

fisetin, alzheimer's disease, safety, tolerability

Brief summary

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Interventions

OTHERFisetin

Fisetin 20mg/kg/day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia * Moca score of 11 or higher * Stable psychotropics and cognitive enhancing medications

Exclusion criteria

* Known hypersensitivity or allergy to fisetin * Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial * Unstable medical disorders * Ongoing treatment for active infection with antibiotics/antifungals * Ongoing treatment for cancer * Active alcohol or substance use disorder * Recent active bleeding * Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin * Use within the last month of other senolytic supplements, antioxidant supplements, natural health products * Other neurologic or neurodegenerative conditions impacting cognition * Active Major Depressive Episode, active suicidal thoughts or psychosis * Any thing that would preclude the ability to undergo an MRI scan

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin)	30 days	Measured using AE reports

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORKrista Lanctôt, PhD

Sunnybrook Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026